{"protocolSection":{"identificationModule":{"nctId":"NCT02604654","orgStudyIdInfo":{"id":"SWYY-YQTLKL"},"organization":{"fullName":"The First Hospital of Jilin University","class":"OTHER"},"briefTitle":"Effectiveness and Safety of Yiqitongluo Granule for Stroke","officialTitle":"Phase IV Clinical Trial of Yiqitongluo Granule in the Treatment of Stroke With Qi-deficiency and Blood-stasis Syndrome"},"statusModule":{"statusVerifiedDate":"2020-07","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2015-12-29","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2017-11-05","type":"ACTUAL"},"completionDateStruct":{"date":"2017-12-06","type":"ACTUAL"},"studyFirstSubmitDate":"2015-11-11","studyFirstSubmitQcDate":"2015-11-11","studyFirstPostDateStruct":{"date":"2015-11-13","type":"ESTIMATED"},"lastUpdateSubmitDate":"2021-08-19","lastUpdatePostDateStruct":{"date":"2021-08-25","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR_INVESTIGATOR","investigatorFullName":"Yi Yang","investigatorTitle":"Associated Dean of First Hospital of Jilin University","investigatorAffiliation":"The First Hospital of Jilin University"},"leadSponsor":{"name":"Yi Yang","class":"OTHER"},"collaborators":[{"name":"Shineway Pharmaceutical Co.,Ltd","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The purpose of the prospective study is to evaluate the effectiveness and safety of Yiqitongluo granule in the treatment of stroke with qi-deficiency and blood-stasis in more than sixy hospitals all over China."},"conditionsModule":{"conditions":["Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE4"],"designInfo":{"allocation":"NA","interventionModel":"SINGLE_GROUP","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":2197,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Yiqitongluo group","type":"EXPERIMENTAL","description":"Yiqitongluo granule 12g each time, 3 times a daily for 4 weeks.","interventionNames":["Drug: Yiqitongluo granule"]}],"interventions":[{"type":"DRUG","name":"Yiqitongluo granule","description":"administered after dissolved","armGroupLabels":["Yiqitongluo group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Safety of Yiqitongluo for stroke measured by laboratory index","timeFrame":"change from baseline laboratory index at 28(±7) days"}],"secondaryOutcomes":[{"measure":"Effect of Yiqitongluo for stroke with mRS","description":"mRS: modified Rankin Scale","timeFrame":"90(±7) days"},{"measure":"Effect of Yiqitongluo for stroke with syndrome of traditional Chinese medicine","timeFrame":"28(±7) days"},{"measure":"Effect of Yiqitongluo for stroke with NIHSS","description":"NIHSS: the NIH stroke scale","timeFrame":"28(±7) days"},{"measure":"Effect of Yiqitongluo for stroke with BI","description":"BI: Barthel Index","timeFrame":"28(±7) days"},{"measure":"Effect of Yiqitongluo for stroke with EQ-5D","description":"The EQ-5D-3L essentially consists of 2 pages - the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system comprises the following 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, extreme problems.","timeFrame":"28(±7) days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* mild and moderate ischemic stroke patient with 4-25 NIHSS score\n* stable patients within 1 week to 3 months\n* sign informed consent before study\n\nExclusion Criteria:\n\n* CT shows cerebral hemorrhage disease: such as hemorrhagic stroke, epidural hematoma, intracranial hematoma, ventricular hemorrhage, and subarachnoid hemorrhage\n* severe disturbance of consciousness\n* dysphagia\n* TIA\n* hemorrhagic diathesis\n* patient with malignant tumor whose expected lifetime is less than 3 months\n* allergic constitution\n* gestation period, lactation period, woman with the possibility or plan of pregnancy\n* those who participated in other clinical trials within 3 months or taking part in other clinical trials","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Yi Yang","affiliation":"The First Hospital of Jilin University","role":"STUDY_CHAIR"},{"name":"Zhenni Guo","affiliation":"The First Hospital of Jilin University","role":"STUDY_DIRECTOR"}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M16045","name":"Syndrome","relevance":"LOW"},{"id":"M4736","name":"Blind Loop Syndrome","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"BC06","name":"Digestive System Diseases"},{"abbrev":"BC18","name":"Nutritional and Metabolic Diseases"}]}},"hasResults":false}